CN113082071A - Chinese patent medicine preparation for pneumonia and preparation method thereof - Google Patents
Chinese patent medicine preparation for pneumonia and preparation method thereof Download PDFInfo
- Publication number
- CN113082071A CN113082071A CN202110269176.7A CN202110269176A CN113082071A CN 113082071 A CN113082071 A CN 113082071A CN 202110269176 A CN202110269176 A CN 202110269176A CN 113082071 A CN113082071 A CN 113082071A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese patent
- patent medicine
- medicine preparation
- pneumonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 36
- 239000000843 powder Substances 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 16
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 claims abstract description 15
- 229940089837 amygdalin Drugs 0.000 claims abstract description 15
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 claims abstract description 15
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 claims abstract description 15
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 claims abstract description 11
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 claims abstract description 11
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 claims abstract description 11
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 claims abstract description 11
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930194248 Licoflavone Natural products 0.000 claims abstract description 10
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 claims abstract description 9
- CYBWUNOAQPMRBA-NDTOZIJESA-N platycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CYBWUNOAQPMRBA-NDTOZIJESA-N 0.000 claims abstract description 9
- GWBIYORWNUYYMZ-UHFFFAOYSA-N platycodin D Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(O)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O GWBIYORWNUYYMZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 claims abstract description 8
- 229930192014 saikosaponin Natural products 0.000 claims abstract description 7
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 4
- 239000000243 solution Substances 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 238000000605 extraction Methods 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 235000015203 fruit juice Nutrition 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 238000001953 recrystallisation Methods 0.000 claims description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 5
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 5
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 238000005189 flocculation Methods 0.000 claims description 5
- 230000016615 flocculation Effects 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 229930189407 platycodin Natural products 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 4
- 150000002215 flavonoids Chemical class 0.000 claims description 4
- 235000017173 flavonoids Nutrition 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 3
- 238000000643 oven drying Methods 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- 235000011477 liquorice Nutrition 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 230000002411 adverse Effects 0.000 abstract description 4
- 206010011224 Cough Diseases 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 241001570521 Lonicera periclymenum Species 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000013078 crystal Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000555712 Forsythia Species 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 5
- 244000018633 Prunus armeniaca Species 0.000 description 5
- 235000009827 Prunus armeniaca Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 5
- 229960004949 glycyrrhizic acid Drugs 0.000 description 5
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 5
- 235000019410 glycyrrhizin Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 244000144725 Amygdalus communis Species 0.000 description 4
- DTOUWTJYUCZJQD-UJERWXFOSA-N Forsythiaside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H](O)[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O1 DTOUWTJYUCZJQD-UJERWXFOSA-N 0.000 description 4
- 239000004378 Glycyrrhizin Substances 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241000204003 Mycoplasmatales Species 0.000 description 4
- 240000003582 Platycodon grandiflorus Species 0.000 description 4
- 229940124350 antibacterial drug Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- -1 forsythol Chemical class 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 2
- 240000005528 Arctium lappa Species 0.000 description 2
- 235000003130 Arctium lappa Nutrition 0.000 description 2
- 241000202726 Bupleurum Species 0.000 description 2
- 241000510654 Bupleurum chinense Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- PGCKDCPTJAQQSQ-UHFFFAOYSA-N Isolicoflavonol Chemical compound C1=C(O)C(CC=C(C)C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 PGCKDCPTJAQQSQ-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 2
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 108010093305 exopolygalacturonase Proteins 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 2
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 2
- 150000008130 triterpenoid saponins Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000213015 Bupleurum scorzonerifolium Species 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- DTOUWTJYUCZJQD-QJDQKFITSA-N Forsythiaside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O DTOUWTJYUCZJQD-QJDQKFITSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 241000558306 Gynocardia odorata Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229930182499 Lappaol Natural products 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 206010035724 Pneumonia mycoplasmal Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- KYWSCMDFVARMPN-MSSMMRRTSA-N Saikosaponin A Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-MSSMMRRTSA-N 0.000 description 1
- VJEMOEYSQDKAQF-MJKDWHOWSA-N Saikosaponin C Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2C([C@H]3[C@](C4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)O[C@@H]1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VJEMOEYSQDKAQF-MJKDWHOWSA-N 0.000 description 1
- VSVPCEFIECVNTB-UHFFFAOYSA-N Saikosaponin c Natural products CC1OC(OC2C(O)C(O)C(OC3CCC4(C)C(C3)C(C)(C)CC5(C)C4C=CC67OCC8(CCC(C)(C)CC68)C(O)CC57C)OC2COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C1O VSVPCEFIECVNTB-UHFFFAOYSA-N 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010043521 Throat irritation Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- KGGGRGBDMBZXKF-UHFFFAOYSA-N Virganreagenin G Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C KGGGRGBDMBZXKF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ZDKCXSMMRXSSDE-UHFFFAOYSA-N chikusakoside II Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)OC1COC1C(O)C(O)C(O)C(CO)O1 ZDKCXSMMRXSSDE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- PXQNZQURQNZGKZ-MXNHKPIDSA-N platycodin D2 Chemical group O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PXQNZQURQNZGKZ-MXNHKPIDSA-N 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- VJEMOEYSQDKAQF-UHFFFAOYSA-N saikogenin E 3-O-beta-D-glucopyranosyl-(1?6)-[alpha-L-rhamnopyranosyl-(1?4)]-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)OC1COC1C(O)C(O)C(O)C(CO)O1 VJEMOEYSQDKAQF-UHFFFAOYSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The pneumonia Chinese patent medicine preparation is prepared from the following raw materials in parts by weight: 40-50 parts of honeysuckle dry extract powder, 8-10 parts of phillyrin A, 5-10 parts of arctigenin, 1-5 parts of platycodin D, 2-5 parts of saikosaponin, 2-6 parts of amygdalin and 1-10 parts of licoflavone; the Chinese patent medicine preparation for treating pneumonia disclosed by the invention takes pure Chinese medicinal materials as raw materials, extracts effective components aiming at pneumonia, has a quicker effect compared with the traditional Chinese medicine taken directly, is convenient to take, avoids adverse effects of body fatness, drug resistance and the like caused by taking a large amount of western medicine antibiotics, can radically treat pneumonia, and is not easy to relapse.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the field of Chinese patent medicine preparation, in particular to a Chinese patent medicine preparation for treating pneumonia and a preparation method thereof.
[ background of the invention ]
Pneumonia, the name of the disease, pneumonia is one of the common diseases of internal medicine and pediatrics, also called lung block, cough and dyspnea due to lung wind and phlegm, is characterized by fever, cough, excessive phlegm, dyspnea and suffocation, and the like, and the disease is acute in onset, rapid in change and multiple in complications; pneumonia is caused by pathogenic microorganisms such as bacteria, viruses, fungi and parasites, and physicochemical factors such as radiation and inhaled foreign matters; at present, the symptoms can be relieved and the course of disease can be shortened by using proper antibacterial drugs in the early stage of the mycoplasma pneumoniae of children, macrolide antibacterial drugs are the first choice, such as erythromycin, roxithromycin and azithromycin, fluoroquinolones such as levofloxacin, gatifloxacin, moxifloxacin and the like, tetracyclines are also used for treating the mycoplasma pneumoniae, and the treatment course is generally 2-3 weeks. Because mycoplasma pneumoniae has no cell wall, penicillin or cephalosporin antibacterial drugs are ineffective. For severe cough, antitussive should be given properly. If secondary bacterial infection occurs, targeted antibacterial drugs can be selected for treatment according to the pathogenic inspection of sputum; however, the above therapeutic drugs are mainly western medicines and antibiotics, and have certain limitations, such as large side effects on the body after long-term administration and easy recurrence after drug withdrawal.
Therefore, the problem to be solved in the field is to provide a Chinese patent medicine preparation for treating pneumonia and a preparation method thereof without side effect.
[ summary of the invention ]
Aiming at the problems, the Chinese patent medicine preparation for pneumonia provided by the invention takes pure Chinese medicinal materials as raw materials, extracts effective components aiming at pneumonia, has a faster effect compared with the traditional Chinese medicine taken directly, is convenient to take, avoids adverse effects such as body fatness and drug resistance caused by taking a large amount of western medicine antibiotics, can radically treat pneumonia, and is not easy to relapse.
In order to solve the problems, the invention provides a Chinese patent medicine preparation for pneumonia, which is prepared from the following raw materials in parts by weight: 40-50 parts of honeysuckle dry paste powder, 8-10 parts of forsythin A, 5-10 parts of arctigenin, 5-5 parts of platycodin D1, 2-5 parts of saikoside, 2-6 parts of amygdalin and 1-10 parts of licoflavone.
Further, the pneumonia Chinese patent medicine preparation is prepared from the following raw materials in parts by weight: 45 parts of honeysuckle dry paste powder, 9 parts of phillyrin A, 8 parts of arctigenin, 2 parts of platycodin D, 3 parts of saikosaponin, 4 parts of amygdalin and 5 parts of licoflavone.
A preparation method of a Chinese patent medicine preparation for treating pneumonia comprises the following steps:
the method comprises the following steps: preparing honeysuckle dry paste powder by twice decoction, decompression concentration and vacuum drying;
step two: obtaining forsythin A by extraction, chromatographic column refining and recrystallization;
step three: preparing arctigenin through extraction, membrane separation, crystallization and recrystallization;
step four: extracting platycodin D with ethanol solution;
step five: soaking in ethanol solution, heating, extracting, and oven drying to obtain saikosaponin powder;
step six: the amygdalin is prepared by squeezing to remove oil, drying and crushing, ultrasonic microwave extraction and petroleum ether extraction;
step seven: the liquorice total flavonoids are prepared by ultrasonic enzymolysis, flocculation impurity removal and macroporous resin column adsorption.
Further, the density of the extract obtained by vacuum concentration in the step one is 1.20-1.30.
Further, in the second step, each extraction time is 60-120min, the heating reflux extraction is carried out for three times, and the extraction is carried out for 2-4 times by adopting water saturated n-butanol.
Further, the platycodin D is extracted as follows: crushing platycodon grandiflorum raw materials, stirring and extracting 90% ethanol water solution with the mass 5 times of that of the raw materials at 80 ℃ for 2 times to obtain extract, separating the extract by adopting an ultrafiltration membrane with the molecular weight cutoff of 10000-.
Further, in the fifth step, soaking is performed by adopting a 60% ethanol solution, and sodium dodecyl sulfate is added.
Further, in the sixth step, during ultrasonic microwave extraction, the ultrasonic waves are controlled to be normally opened at 200W, the microwave power is 200-300W, and the extraction is carried out for 10-15 min.
Further, in the seventh step, ultrasonic enzymolysis is carried out by using a complex enzyme solution with the mass concentration of 0.05-0.15%, adding 10-30 ml of the complex enzyme solution per 1g of licorice root residue, and carrying out ultrasonic treatment at 40-60 ℃ for 0.5-1.5 h at 50KHZ and 160W.
Further, the flocculation impurity removal in the seventh step is carried out at the temperature of 60 ℃, chitosan is added into the concentrated solution according to the proportion of 80mL of chitosan colloidal solution to 1000mL of concentrated solution, the mixture is fully stirred, then 101 fruit juice clarifier aqueous solution is added according to the proportion of 80mL of 101 fruit juice clarifier aqueous solution to 1000mL of concentrated solution, the mixture is fully stirred, the mixture is kept stand overnight, and centrifugal separation is carried out to obtain supernatant.
Moreover, the Chinese patent medicine preparation for pneumonia of the invention takes pure Chinese medicinal materials as raw materials, extracts effective components aiming at pneumonia, has quicker effect and convenient taking compared with the direct taking of the Chinese medicine, avoids the adverse effects of body fatness, drug resistance and the like caused by taking a large amount of western medicine antibiotics, can fundamentally treat pneumonia, and is not easy to relapse.
[ detailed description ] embodiments
The invention discloses a Chinese patent medicine preparation for treating pneumonia and a preparation method thereof, and a person skilled in the art can realize the preparation by properly improving process parameters by referring to the content of the invention. It is expressly intended that all such similar substitutes and modifications which would be obvious to those skilled in the art are deemed to be included in the invention. While the method and application of the present invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the method and application described herein may be made and equivalents employed without departing from the spirit and scope of the invention.
For a further understanding of the present invention, reference will now be made in detail to the following examples.
The Chinese patent medicine preparation for treating pneumonia is prepared from the following raw materials in parts by weight: 40-50 parts of honeysuckle dry paste powder, 8-10 parts of forsythin A, 5-10 parts of arctigenin, 5-5 parts of platycodin D1, 2-5 parts of saikoside, 2-6 parts of amygdalin and 1-10 parts of licoflavone.
Preferably, the honeysuckle dry paste powder is 45 parts, the forsythia fruit lipoid A9 parts, the arctigenin is 8 parts, the platycodin D2 parts, the saikosaponin is 3 parts, the amygdalin is 4 parts, and the licoflavone is 5 parts.
Honeysuckle flower: dried flower bud or flower with initial bloom of plant of Lonicera of Caprifoliaceae, sweet taste, and cold nature; the Chinese medicinal composition enters lung and has the effects of clearing away heat and toxic materials and dispelling wind and heat; contains volatile oil, luteolin, inositol, flavonoids, inositol, saponin, tannin, etc. The separated chlorogenic acid and isochlorogenic acid are the main antibacterial components of honeysuckle.
Fructus forsythiae: the dry fruit of forsythia suspense, a forsythia of the oleaceae family, contains triterpenoid saponin, the peel contains sterol, forsythol, alkaloid, saponin, oleanolic acid and coumarins, and also contains abundant vitamin P and a small amount of volatile oil, has broad-spectrum antibacterial, anti-inflammatory and antipyretic effects, has strong inhibitory effect on staphylococcus aureus and dysentery bacillus as main antibacterial components, and also has a certain inhibitory effect on other pathogenic bacteria, influenza virus and leptospira.
And (3) burdock: dried mature fruit of Arctium lappa L of Compositae, with pungent, bitter and cold properties; the lung-entering preparation contains arctiin, fatty oil, lappaol, vitamin A, vitamin B1, alkaloid and the like, and is suitable for influenza, acute bronchitis, acute tracheitis, viral pneumonia and the like.
Balloon flower: the dried root of Platycodon grandiflorum of Campanulaceae contains multiple saponins, mainly platycodin, and the sapogenins generated by completely hydrolyzing multiple mixed saponins include platycodin, polygalacic acid, and small amount of platycodon acid. In addition, inulin, phytosterol and the like are contained, and the effects of dispersing lung qi, eliminating phlegm, relieving sore throat and expelling pus are achieved.
Bupleurum root: dried root of Bupleurum chinense DC or Bupleurum scorzonerifolium DC of Umbelliferae, wherein the Bupleurum chinense DC contains alpha-spinasterol, phorbol alcohol, saikosaponin a, c, d, and volatile oil. Radix bupleuri chinensis contains saikoside a, c, d, volatile oil, bupleurum alcohol, chaulmoogra alcohol, alpha-spinasterol, etc. Bupleuri radix and its effective component saikoside have anti-inflammatory effect, which is related to promoting adrenal cortex system function, etc., and saikoside has effect of reducing plasma cholesterol. Radix bupleuri has good effects of resisting fatty liver, resisting liver injury, promoting bile flow, reducing transaminase, exciting smooth muscle of intestine, inhibiting gastric acid secretion, resisting ulcer, inhibiting trypsin, etc.
Almond: seeds of apricot, wild apricot and northeast apricot of Prunus of Rosaceae contain amygdalin, fatty oil, protein and various free amino acids. Contains amygdalase, chlorogenic acid, inositol, benzaldehyde, linalool, etc. and has anti-mutation effect and obvious anti-inflammatory and analgesic effect.
Licorice root: dried root and rhizome of Glycyrrhiza uralensis Fisch, Glycyrrhiza inflata Bat or Glycyrrhiza glabra L of Glycyrrhiza of Leguminosae contains triterpenoid saponin glycyrrhizic acid, potassium and calcium salt of glycyrrhizin are glycyrrhizin, which is sweet component in Glycyrrhiza uralensis Fisch, and 2 molecules of glucuronic acid and 1 molecule of 18 beta-glycyrrhetinic acid are generated after hydrolysis. Contains glycyrrhizin A3, B2, C2, D3, F3, G2, H2, J2 and K2. The flavonoids separated from Glycyrrhrizae radix are more, and are effective components for resisting ulcer and relieving spasm, and have effects of removing toxic substance, relieving spasm and pain, and harmonizing drug property, such as New Zealand vitexin II, licoflavone, isolicoflavonol, and glycyrrhizin etc.
A preparation method of a Chinese medicinal preparation for treating pneumonia comprises:
the method comprises the following steps: preparing honeysuckle dry paste powder
(1) Primary decoction: adding flos Lonicerae into 8-12 times of water by weight of flos Lonicerae to obtain primary extractive solution, vacuumizing the primary extractive solution, heating to 60-80 deg.C to boil the primary extractive solution, keeping the temperature for 1-3 hr, and filtering to obtain primary filtrate and residue;
(2) and (3) secondary decoction: adding the filter residue obtained in the step (1) into water 7-9 times the weight of the filter residue to obtain a secondary immersion liquid, vacuumizing the secondary immersion liquid, heating to 60-80 ℃ to boil the secondary immersion liquid, preserving heat for 1-3h, and filtering to obtain a secondary filtrate;
(3) and (3) concentrating under reduced pressure: merging the primary filtrate obtained in the step (1) and the secondary filtrate obtained in the step (2), and then carrying out reduced pressure concentration to obtain an extract with the relative density of 1.20-1.30;
(4) and (3) vacuum drying: vacuum drying the extract obtained in the step (3) to obtain honeysuckle dry paste powder
Step two: preparation of Forsythiaside A
(1) Extraction: taking dry forsythia suspense leaves, crushing to 50-70 meshes to obtain forsythia suspense powder, adding 11-20 times of 50-80% ethanol by mass of the forsythia suspense powder, extracting for 60-120 minutes each time, heating and refluxing for three times, combining and filtering extracting solutions obtained in the three times, and concentrating filtrate at 60 ℃ until no alcohol smell exists;
(2) and (3) extraction: dissolving the concentrate obtained in the step (1) in water to obtain an extracting solution; then, adjusting the pH value to 6, and adding petroleum ether for extraction to remove fat-soluble pigments; then, extracting with water saturated n-butanol to remove most of water-soluble impurities; wherein the amount of water saturated n-butanol is 0.5-2 times of the extractive solution by volume ratio; extracting for 2-4 times, recovering n-butanol to obtain forsythiaside A extract;
(3) refining by a chromatographic column: passing the forsythoside A extract through a 200-mesh-300-mesh silica gel column by a dry method, eluting with a mixed solution of ethyl acetate and methanol, wherein the volume ratio of the ethyl acetate to the methanol is 7: 1, collecting an eluent, and concentrating to dryness to obtain a crude crystal;
(4) and (3) recrystallization: dissolving the obtained crude crystal with anhydrous ethanol, slightly heating, cooling after completely dissolving, then placing in a refrigerator for recrystallization at 1-6 deg.C, and after 12 hr, vacuum filtering to obtain forsythiaside A crystal; then, repeating the recrystallization step for 2-3 times; and finally drying to obtain a finished product.
Step three: preparation of arctigenin
(1) Extraction: pulverizing fructus Arctii into 10-40 mesh powder, reflux-extracting with methanol for 2-3 times, mixing extractive solutions, and decolorizing with activated carbon to obtain decolorized solution;
(2) membrane separation: filtering the decolorized solution with microfiltration membrane, ultrafiltering with ultrafiltration membrane, and collecting the filtrate; enzymolysis and transformation: concentrating the permeate without alcohol, adjusting pH, and adding complex enzyme for enzymolysis;
(3) and (3) crystallization: centrifuging the enzymolysis solution, refluxing and dissolving the centrifugate with chloroform, standing for crystallization, and filtering to obtain a crude crystal;
(4) and (3) recrystallization: and dissolving the crude crystal with methanol for crystallization, and drying to obtain the product.
Step four: extracting platycodin D
Crushing platycodon grandiflorum raw materials, stirring and extracting 90% ethanol water solution with the mass 5 times of that of the raw materials at 80 ℃ for 2 times to obtain extract, separating the extract by adopting an ultrafiltration membrane with the molecular weight cutoff of 10000-.
Step five: extracting saikosaponin
Pulverizing bupleuri radix to 16 mesh, soaking in 60% ethanol solution, adding sodium dodecyl sulfate (K12), heating for 10min, standing, filtering, adding 60% ethanol solution into the residue, soaking, heating for 10min, standing, filtering, mixing filtrates, evaporating to remove solvent, and maintaining water bath temperature at 50 + -5 deg.C. Extracting with n-butanol at 55 deg.C, evaporating most of n-butanol, oven drying at 50 deg.C, and grinding to obtain yellow total saponin powder.
Step six: extracting amygdalin
Taking bitter almond (with peel) and putting the bitter almond into boiling water (90-100 ℃) for decocting for about 5 minutes, taking out and peeling; squeezing the peeled bitter almond to remove oil, drying and crushing the cake dregs; adding 5-7 times of 40-60% ethanol solution into crushed bitter apricot kernels, placing the crushed bitter apricot kernels in an ultrasonic-microwave extractor, controlling the ultrasonic wave to be 200W (normally open) and the microwave power to be 200-300W, extracting for 10-15 min, filtering, repeatedly extracting filter residues once, and combining filter liquor; extracting the filtrate for three times by using petroleum ether (60-90 ℃), and recovering the petroleum ether under reduced pressure to obtain a concentrate; adding absolute ethanol into the concentrate to dissolve, refrigerating, standing, precipitating amygdalin, repeatedly crystallizing for 2 times to obtain amygdalin white crystal, and washing the crystal with diethyl ether and ethanol for 2-3 times to obtain amygdalin with purity of more than 99%.
Step seven: extraction of licoflavone
(1) Ultrasonic enzymolysis: adding a complex enzyme solution with the mass concentration of 0.05-0.15% into dried and crushed licorice roots, adding 10-30 ml of the complex enzyme solution per 1g of the licorice roots, adjusting the pH value of the solution to 4.5-6, carrying out ultrasonic treatment at 40-60 ℃ for 0.5-1.5 hours at 160W at 50KHZ for 0.5-1.5 hours, rapidly heating to 90 ℃, keeping for 10min to inactivate enzyme, filtering, collecting filtrate, and concentrating under reduced pressure to obtain a concentrated solution with the relative density of 1.05 at 60 ℃; wherein the complex enzyme is a mixture of cellulase and pectinase, and the mass ratio of the cellulase to the pectinase is 1: 1;
(2) flocculation impurity removal: adding chitosan into the concentrated solution according to the proportion of 80mL of chitosan colloidal solution to 1000mL of concentrated solution at 60 ℃, fully stirring, adding 101 fruit juice clarifier aqueous solution according to the proportion of 80mL of 101 fruit juice clarifier aqueous solution to 1000mL of concentrated solution, fully stirring, standing overnight, performing centrifugal separation, and taking supernatant; wherein, the chitosan colloidal solution is an acetic acid solution with the mass concentration of 1% which is prepared by mixing an acetic acid solution with the volume concentration of 1% and chitosan, and the 101 fruit juice clarifier aqueous solution is an aqueous solution with the mass concentration of 5% which is prepared by mixing water and a 101 fruit juice clarifier;
(3) passing through a macroporous resin column: passing the supernatant through D101 resin column, eluting with 50% ethanol, concentrating the eluate, and drying under reduced pressure to obtain Glycyrrhrizae radix total flavone
Step eight: mixing the flos Lonicerae dry extract powder, phillyrin A, arctigenin, platycodin D, saikoside, amygdalin and licoflavone in proportion to obtain Chinese medicinal preparation powder.
Criteria for efficacy assessment
1. And (3) curing: the symptoms of pneumonia caused by the mycoplasma pneumoniae disappear, other symptoms such as cough, pharyngalgia, nausea, headache and the like also disappear, and the pathological examination is normal.
2. Improvement: the symptoms of the pneumonia caused by the mycoplasma pneumoniae are obviously relieved, the constitution is gradually recovered, and other clinical symptoms are gradually recovered.
3. The disease is not cured: there was no improvement in mycoplasma pneumoniae pneumonia and other clinical symptoms.
Typical cases are:
wangzhi, female, 7 years old, diagnosed in 2018 in 11 months and 2 days, with symptoms: after the cough is cured, the cough is not persistent, little and white phlegm is easy to cough, and the cough is sweaty. Chest CT scans showed two pneumonia events. Body temperature was slightly elevated. And (3) diagnosis: pneumonia. After the traditional Chinese medicine is taken for one treatment course, the symptoms of fever and cough are relieved, and after the continuous taking of 15 doses, the body is completely recovered, and the chest tablets are normal.
Plum, male, 6 years old, 2 months and 13 days in 2019, and symptoms: cough for 10 days, fatigue of the whole body, headache, little and white sputum and easy expectoration. And (4) checking: the tongue is pale red, the pulse is thready and wiry, the blood cell analysis is normal, and CT scanning of the chest shows two pneumonia. And (3) diagnosis: pneumonia. Treatment: after the traditional Chinese medicine is taken for two courses of treatment, the body is completely recovered. The chest radiograph is normal.
To date, men, 11 years old, and 2020, 4 months and 2 days, symptoms: cough 24 days, little sputum, white color, easy expectoration, sweating during cough, no dry and itchy throat, no dry and bitter mouth and normal stool. And (4) checking: the tongue coating is white, greasy and thick, the quality is light red, the pulse is thin and wiry, the blood cell analysis is normal, and CT scanning of the chest shows two pneumonia. And (3) diagnosis: pneumonia. Treatment: after the traditional Chinese medicine is taken for one treatment course, symptoms of fever and cough disappear, and after the continuous taking for 2 treatment courses, the body is completely recovered. The chest radiograph is normal.
The Chinese patent medicine preparation for treating pneumonia disclosed by the invention takes pure Chinese medicinal materials as raw materials, extracts effective components aiming at pneumonia, has a quicker effect compared with the traditional Chinese medicine taken directly, is convenient to take, avoids adverse effects of body fatness, drug resistance and the like caused by taking a large amount of western medicine antibiotics, can radically treat pneumonia, and is not easy to relapse.
Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art.
Claims (10)
1. The pneumonia Chinese patent medicine preparation is characterized by being prepared from the following raw materials in parts by weight: 40-50 parts of honeysuckle dry paste powder, 8-10 parts of forsythin A, 5-10 parts of arctigenin, 5-5 parts of platycodin D1, 2-5 parts of saikoside, 2-6 parts of amygdalin and 1-10 parts of licoflavone.
2. The pneumonia Chinese patent medicine preparation according to claim 1 is prepared from the following raw materials in parts by weight: 45 parts of honeysuckle dry paste powder, 9 parts of phillyrin A, 8 parts of arctigenin, 2 parts of platycodin D, 3 parts of saikosaponin, 4 parts of amygdalin and 5 parts of licoflavone.
3. A method for preparing the Chinese patent medicine preparation applied to claim 1, which is characterized by comprising the following steps:
the method comprises the following steps: preparing honeysuckle dry paste powder by twice decoction, decompression concentration and vacuum drying;
step two: obtaining forsythin A by extraction, chromatographic column refining and recrystallization;
step three: preparing arctigenin through extraction, membrane separation, crystallization and recrystallization;
step four: extracting platycodin D with ethanol solution;
step five: soaking in ethanol solution, heating, extracting, and oven drying to obtain saikosaponin powder;
step six: the amygdalin is prepared by squeezing to remove oil, drying and crushing, ultrasonic microwave extraction and petroleum ether extraction;
step seven: the liquorice total flavonoids are prepared by ultrasonic enzymolysis, flocculation impurity removal and macroporous resin column adsorption.
4. The method for preparing a Chinese patent medicine preparation according to claim 3, wherein the density of the extract obtained by the concentration under reduced pressure in the first step is 1.20-1.30.
5. The method for preparing a Chinese patent medicine preparation according to claim 3, wherein each extraction time in the second step is 60-120min, the extraction is performed under heating and refluxing for three times, and the extraction is performed 2-4 times by using water saturated n-butanol.
6. The method for preparing a Chinese patent medicine preparation according to claim 3, wherein the extracted platycodin D is as follows: crushing platycodon grandiflorum raw materials, stirring and extracting 90% ethanol water solution with the mass 5 times of that of the raw materials at 80 ℃ for 2 times to obtain extract, separating the extract by adopting an ultrafiltration membrane with the molecular weight cutoff of 10000-.
7. The method for preparing a Chinese patent medicine preparation according to claim 3, wherein the soaking in the fifth step is performed by adopting a 60% ethanol solution, and sodium dodecyl sulfate (K12) is added.
8. The method for preparing a Chinese patent medicine preparation according to claim 3, wherein in the sixth step, the ultrasonic wave is extracted with microwave at 200W to 300W for 10 to 15min under a normal condition of 200W.
9. The preparation method of the Chinese patent medicine preparation according to claim 3, wherein the ultrasonic enzymolysis in the seventh step adopts a complex enzyme solution with the mass concentration of 0.05-0.15%, the amount of the complex enzyme solution added is 10-30 ml per 1g of licorice root residue, and the ultrasonic treatment is carried out at 40-60 ℃ for 0.5-1.5 h at the temperature of 50KHZ and 160W.
10. The preparation method of a Chinese patent medicine preparation according to claim 3, wherein the flocculation impurity removal in the seventh step is performed at 60 ℃, chitosan is added to the concentrated solution according to the ratio of 80mL of chitosan colloidal solution to 1000mL of concentrated solution, the mixture is fully stirred, 101 fruit juice clarifier aqueous solution is added according to the ratio of 80mL of 101 fruit juice clarifier aqueous solution to 1000mL of concentrated solution, the mixture is fully stirred, kept stand overnight, centrifuged, and supernatant is obtained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110269176.7A CN113082071A (en) | 2021-03-12 | 2021-03-12 | Chinese patent medicine preparation for pneumonia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110269176.7A CN113082071A (en) | 2021-03-12 | 2021-03-12 | Chinese patent medicine preparation for pneumonia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113082071A true CN113082071A (en) | 2021-07-09 |
Family
ID=76667237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110269176.7A Pending CN113082071A (en) | 2021-03-12 | 2021-03-12 | Chinese patent medicine preparation for pneumonia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113082071A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115040619A (en) * | 2022-05-27 | 2022-09-13 | 博济医药科技股份有限公司 | A Chinese medicinal composition and its application in preparing medicine for treating pneumonia |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101168558A (en) * | 2006-10-25 | 2008-04-30 | 黑龙江大学 | A New Method of Extracting Saikosaponin from Bupleuri |
| CN101748169A (en) * | 2010-01-12 | 2010-06-23 | 南京泽朗医药科技有限公司 | Method for preparing arctigenin from burdock |
| CN103142682A (en) * | 2013-02-28 | 2013-06-12 | 惠州市九惠制药股份有限公司 | Method for extracting liquorice flavonoids from liquorice residue |
| CN104177455A (en) * | 2014-09-04 | 2014-12-03 | 南京标科生物科技有限公司 | Method for extracting amygdalin from bitter almond |
| CN104530174A (en) * | 2014-12-16 | 2015-04-22 | 陕西嘉禾植物化工有限责任公司 | Method for extracting platycodin D from platycodon grandiflorum |
| CN105085587A (en) * | 2015-08-05 | 2015-11-25 | 湖北济世药业有限责任公司 | Extraction and purification process method for forsythiaside A in fructus forsythiae leaves |
| CN105250471A (en) * | 2015-11-04 | 2016-01-20 | 安徽益健堂中药饮片科技有限公司 | Traditional Chinese medicine composition for treating pneumonia |
| CN108030798A (en) * | 2017-12-12 | 2018-05-15 | 广东广发制药有限公司 | Honeysuckle extracting method, honeysuckle dried cream powder and honeysuckle detoxicating capsule and preparation method |
-
2021
- 2021-03-12 CN CN202110269176.7A patent/CN113082071A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101168558A (en) * | 2006-10-25 | 2008-04-30 | 黑龙江大学 | A New Method of Extracting Saikosaponin from Bupleuri |
| CN101748169A (en) * | 2010-01-12 | 2010-06-23 | 南京泽朗医药科技有限公司 | Method for preparing arctigenin from burdock |
| CN103142682A (en) * | 2013-02-28 | 2013-06-12 | 惠州市九惠制药股份有限公司 | Method for extracting liquorice flavonoids from liquorice residue |
| CN104177455A (en) * | 2014-09-04 | 2014-12-03 | 南京标科生物科技有限公司 | Method for extracting amygdalin from bitter almond |
| CN104530174A (en) * | 2014-12-16 | 2015-04-22 | 陕西嘉禾植物化工有限责任公司 | Method for extracting platycodin D from platycodon grandiflorum |
| CN105085587A (en) * | 2015-08-05 | 2015-11-25 | 湖北济世药业有限责任公司 | Extraction and purification process method for forsythiaside A in fructus forsythiae leaves |
| CN105250471A (en) * | 2015-11-04 | 2016-01-20 | 安徽益健堂中药饮片科技有限公司 | Traditional Chinese medicine composition for treating pneumonia |
| CN108030798A (en) * | 2017-12-12 | 2018-05-15 | 广东广发制药有限公司 | Honeysuckle extracting method, honeysuckle dried cream powder and honeysuckle detoxicating capsule and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 程荣朵等: "中西医结合治疗小儿支气管肺炎50例", 《时珍国医国药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115040619A (en) * | 2022-05-27 | 2022-09-13 | 博济医药科技股份有限公司 | A Chinese medicinal composition and its application in preparing medicine for treating pneumonia |
| CN115040619B (en) * | 2022-05-27 | 2023-08-08 | 博济医药科技股份有限公司 | Traditional Chinese medicine composition and application thereof in preparation of medicine with function of treating pneumonia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ou-Yang et al. | Dioscorea nipponica Makino: a systematic review on its ethnobotany, phytochemical and pharmacological profiles | |
| CN102524474B (en) | Refreshing and nourishing herbal tea and preparation method thereof | |
| EP4147708A1 (en) | Traditional chinese medicine composition for treating novel coronavirus pneumonia, preparation method, detection method, and use thereof | |
| CN102550782B (en) | Herbaceous cool throat smoothing candy and making method thereof | |
| CN105169012A (en) | Antivirus traditional Chinese medicine composition for livestock and poultry, fermented traditional Chinese medicine and preparation method and application | |
| WO2015172618A1 (en) | Anti-tumor traditional chinese medicine, preparation method therefor, and uses thereof | |
| CN104162036A (en) | Oral liquid for treating dental ulcer and preparation method thereof | |
| CN104127738A (en) | Traditional Chinese medicine for treating bronchiectasia caused by phlegm-heat obstructing lung and a preparation method thereof | |
| CN113082071A (en) | Chinese patent medicine preparation for pneumonia and preparation method thereof | |
| CN108164524B (en) | Fibrauretine, extraction method thereof, fibrauretine capsule and preparation method thereof | |
| CN103623120B (en) | A kind of pharynx-clearing throat-benefiting buccal tablet and preparation method thereof | |
| CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
| CN113018330A (en) | Chinese patent medicine granules for treating cold and preparation method thereof | |
| CN113546139A (en) | Preparation for promoting smooth nasal circulation and preparation method thereof | |
| CN104288451A (en) | Traditional Chinese medicine preparation for treating cellulitis | |
| CN102188483A (en) | Extract for treating pharyngolaryngitis and preparation method thereof | |
| CN114601807B (en) | Preparation method of fritillaria lung-clearing concentrated pills | |
| CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof | |
| CN101810717A (en) | Livestock traditional Chinese medicine composition with function of clearing heat and detoxicating, preparation method and application | |
| CN105663429A (en) | Medicine for treating vesicular beriberi | |
| CN107213343A (en) | A kind of canker sore Chinese medicine ointment containing bletilla and preparation method thereof | |
| CN105902772B (en) | Process for purifying effective components of paris polyphylla, pseudo-ginseng and isatis leaf extract | |
| CN105748697A (en) | New use of traditional Chinese medicine composition in preparing medicine for treating wind-heat common cold | |
| CN116173128A (en) | Traditional Chinese medicine composition and traditional Chinese medicine extract for reducing phlegm and clearing heat and preparation method thereof | |
| CN114984138A (en) | Traditional Chinese medicine composition, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210709 |
|
| RJ01 | Rejection of invention patent application after publication |